Accordingly, NIOSH proposes to place olaparib on the List. NIOSH response: Drugs still under investigation are not included on the List because no scientific information, including information normally provided in package inserts, is available for NIOSH review. Hazardous Drugs: Procedures for Developing the NIOSH List of Hazardous Spill control. 4. The FDA requirements for tested and reported endpoints generally overlap with the NIOSH definition of a hazardous drug. This feature is not available for this document. NIOSH response: The NIOSH List creates no legal obligation for its users; it is informational, not regulatory, in content. documents in the last year, by the Energy Department NIOSH response: Drugs still under investigation are not included on the List because no scientific information, including information normally provided in package inserts, is available for NIOSH review. when determining the potential for adverse health effects of hazardous drugs in healthcare workers. Peer review comment: A statement about the evaluation procedures in the draft Policy and Procedures indicates that NIOSH would only consider human studies. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. Please provide information about your professional experience, if any, of implementing control strategies for exposures to hazardous drugs in healthcare or similar settings. Is there a scientific justification for them? NIOSH response: After scientific review and consideration of input from peer reviewers and public commenters, NIOSH is proposing a reorganization of the List. As cancer therapy has changed from primarily cytotoxic drugs to non-cytotoxic and targeted therapies, there is sometimes a mismatch in general recommendations for safe handling and the hazardous nature of the drugs. . developer tools pages. What improvements could be made to this risk management information to make it more useful to employers and healthcare workers? USP 800 Labeling Requirements | United Ad Label This is because there is insufficient information to establish an exposure limit and, therefore, one should err on the side of caution and apply the ALARA principle. NIOSH's definition of a hazardous drug only covers drugs approved by FDA's Center for Drug Evaluation and Research and is not considered for inclusion on the, Dihydroergotamine AHFS Class: 5-hydroxytryptamine (HT) receptor binder, Ivabradine AHFS Class: Hyperpolarization-activated cyclic nucleotide-gated (HCN) blocker. Comment. NIOSH response: The List is updated any time NIOSH is aware that a drug manufacturer has added special handling information to the patient information for a specific drug. Additional changes to the List, including those drugs proposed for removal from the List, are described in detail in the draft NIOSH List of Hazardous Drugs in Healthcare Settings, 2020, which is available for review in the docket for this activity. Comment: Hazardous drugs should also be identified by UNII code (the unique ingredient identifier used by FDA and USP) on the List. All three draft documents are available in the docket for this activity. 2020-09332 Filed 4-30-20; 8:45 am], updated on 4:15 PM on Monday, May 1, 2023, updated on 8:45 AM on Monday, May 1, 2023. Best-Practices-for-Monitoring-Hazardous-Drug-Surface-Contamination The President of the United States manages the operations of the Executive branch of Government through Executive orders. If available, NIOSH would give preference to them over animal and in vitro studies. Comment: Eight drugs were approved by FDA prior to December 2015, but do not appear on the 2016 List and were not proposed for placement on the List in the February 2018 FRN. Should you have any questions, please contact Tiffany Chan, Associate Scientific Liaison, Healthcare Quality and Safety ( [email protected] ). Additionally, peer reviews provide the Agency with a review of its science; peer reviewers and their credentials are identified in the NIOSH Peer Review Agenda.Start Printed Page 25445, Commenters: NIOSH should identify the criteria used to evaluate study quality and strength, and describe how they are used to critically appraise the quality and risk of bias and other limitations of individual studies; arbitrate conflicting information; and synthesize the totality of animal and human studies data in support of, or opposition to, the listing of a drug as hazardous.. Register (ACFR) issues a regulation granting it official legal status. USP 800> and Other Hazardous Pharmaceuticals Standards and Regulations The rationale for placing interferon beta-1b on the List is that information from the package insert indicated reproductive toxicity: spontaneous abortion in human clinical trials. ET on July 30, 2020. NIOSH response: A drug may be removed from the List based on either a written request from an interested party or a change to the package insert. However, NIOSH did not independently evaluate triazolam. NIOSH Peer Review Agenda, https://www.cdc.gov/niosh/review/peer/isi/healthsafetyrisks.html. The package insert also cites gefitinib as exhibiting teratogenicity. . To view the notice and related materials, visit http://www.regulations.govexternal icon and enter CDC-2020-0046 in the search field and click Search., Comments will be accepted until 11:59 p.m. What additional information would improve the usefulness of this table and why? NIOSH response: NIOSH has evaluated each drug individually and not by class of drug. This convention was prepared to implement USP General Chapter <800> on December 1, 2019, which would have been an enforceable standard for managing sterile and non-sterile hazardous . What structural or format changes could be made to improve the utility of this table? The documents posted on this site are XML renditions of published Federal NIOSH is adding text to clarify the agency's intent. Urofollitropin AHFS Class: Ovulation stimulator. Because there is conflicting evidence about the hazard posed by botulinum toxins to the workers who handle these drugs, NIOSH is not proposing the placement of botulinum toxins on the List at this time and invites additional studies, data, and expert opinions pertinent to this issue in order to evaluate the botulinum toxins more fully. This PDF is
